Overview Dividends

(MRUS) Merus BV - Ratings and Ratios

Exchange: NASDAQ • Country: Netherlands • Currency: USD • Type: Common Stock • ISIN: NL0011606264

Bispecific Antibodies, BIZENGRI, MCLA-158, MCLA-129, ONO-4685

Biotechnology
Market Cap in USD: 7,350m
IPO / Inception: 2016-05-19
Return 12m vs S&P 500: 80.2%

EPS (Earnings per Share)

EPS (Earnings per Share) of MRUS over the last years for every Quarter: "2020-12": -1.06, "2021-03": -0.28, "2021-06": -0.71, "2021-09": -0.39, "2021-12": -0.34, "2022-03": -0.43, "2022-06": -0.13, "2022-09": -0.53, "2022-12": -1.81, "2023-03": -0.86, "2023-06": -0.66, "2023-09": -0.43, "2023-12": -1.04, "2024-03": -0.59, "2024-06": -0.81, "2024-09": -1.46, "2024-12": -0.49, "2025-03": -1.4, "2025-06": -2.23, "2025-09": -1.26, "2025-12": 0,
EPS CAGR: 5.66%
EPS Trend: -26.6%
Last SUE: 2.29
Qual. Beats: 1

Revenue

Revenue of MRUS over the last years for every Quarter: 2020-12: 7.380497, 2021-03: 7.12255, 2021-06: 10.437972, 2021-09: 11.801814, 2021-12: 12.923327, 2022-03: 10.534954, 2022-06: 12.106878, 2022-09: 6.71591, 2022-12: 9.960977, 2023-03: 12.444728, 2023-06: 9.600206, 2023-09: 10.436114, 2023-12: 8.096946, 2024-03: 7.310736, 2024-06: 6.844422, 2024-09: 10.572433, 2024-12: 8.822842, 2025-03: 24.482858, 2025-06: 7.494972, 2025-09: 10.373548, 2025-12: null,
Rev. CAGR: -5.69%
Rev. Trend: -6.0%
Last SUE: 0.23
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 67.9%
Value at Risk 5%th 98.7%
Relative Tail Risk -11.67%
Reward TTM
Sharpe Ratio 1.35
Alpha 97.90
CAGR/Max DD 1.91
Character TTM
Hurst Exponent 0.043
Beta 0.861
Beta Downside 0.773
Drawdowns 3y
Max DD 42.04%
Mean DD 11.84%
Median DD 11.27%

Description: MRUS Merus BV November 05, 2025

Merus N.V. (NASDAQ: MRUS) is a clinical-stage immuno-oncology firm based in Utrecht, the Netherlands, focused on bispecific antibody therapeutics. Its pipeline features BIZENGRI for pancreatic adenocarcinoma and non-small cell lung cancer (NSCLC) patients lacking Neuregulin 1 alterations, MCLA-158 and MCLA-129 for various solid tumors, ONO-4685 for relapsed/refractory T-cell lymphoma, and INCA33890 for advanced solid tumors. The company leverages collaborations with Eli Lilly, Ono Pharmaceutical, and Betta Pharmaceuticals to advance development and commercialization.

As of the latest quarterly filing (Q2 2024), Merus reported roughly €150 million in cash and short-term investments, giving it a runway of about 12-18 months without additional financing. The firm’s R&D spend grew 22 % year-over-year to €45 million, reflecting accelerated pre-clinical and early-clinical activity. In the broader biotech sector, immuno-oncology remains a high-growth sub-industry, with a projected CAGR of ~9 % through 2028, driven by increasing demand for targeted therapies and supportive reimbursement environments in Europe and the U.S.

If you’re interested in a deeper quantitative assessment, ValueRay’s platform provides granular, real-time analytics that can help you evaluate Merus’s valuation relative to peers and sector trends.

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-334.9m TTM) > 0 and > 6% of Revenue (6% = 3.07m TTM)
FCFTA -0.41 (>2.0%) and ΔFCFTA -22.73pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 1010 % (prev 1786 %; Δ -776.3pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.41 (>3.0%) and CFO -317.3m > Net Income -334.9m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 7.97 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (75.7m) change vs 12m ago 10.87% (target <= -2.0% for YES)
Gross Margin -217.5% (prev -175.8%; Δ -41.73pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 6.33% (prev 3.89%; Δ 2.44pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -10.58 (EBITDA TTM -323.7m / Interest Expense TTM 30.8m) >= 6 (WARN >= 3)

Altman Z'' -13.56

(A) 0.67 = (Total Current Assets 590.8m - Total Current Liabilities 74.1m) / Total Assets 772.0m
(B) -1.46 = Retained Earnings (Balance) -1.13b / Total Assets 772.0m
warn (B) unusual magnitude: -1.46 — check mapping/units
(C) -0.40 = EBIT TTM -325.9m / Avg Total Assets 808.3m
(D) -9.99 = Book Value of Equity -1.10b / Total Liabilities 110.4m
Total Rating: -13.56 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 30.24

1. Piotroski 0.0pt
2. FCF Yield -4.66%
3. FCF Margin data missing
4. Debt/Equity 0.02
5. Debt/Ebitda 0.94
6. ROIC - WACC (= -59.08)%
7. RoE -48.76%
8. Rev. Trend -5.97%
9. EPS Trend -26.60%

What is the price of MRUS shares?

As of January 02, 2026, the stock is trading at USD 90.00 with a total of 0 shares traded.
Over the past week, the price has changed by -7.13%, over one month by -6.19%, over three months by -4.41% and over the past year by +114.03%.

Is MRUS a buy, sell or hold?

Merus BV has received a consensus analysts rating of 4.76. Therefore, it is recommended to buy MRUS.
  • Strong Buy: 13
  • Buy: 4
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the MRUS price?

Issuer Target Up/Down from current
Wallstreet Target Price 97 7.8%
Analysts Target Price 97 7.8%
ValueRay Target Price 140.1 55.7%

MRUS Fundamental Data Overview December 27, 2025

Market Cap USD = 7.35b (7.35b USD * 1.0 USD.USD)
P/S = 129.8511
P/B = 9.4852
Beta = 1.062
Revenue TTM = 51.2m USD
EBIT TTM = -325.9m USD
EBITDA TTM = -323.7m USD
Long Term Debt = 9.91m USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 2.36m USD (from shortTermDebt, last quarter)
Debt = 10.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -303.2m USD (from netDebt column, last quarter)
Enterprise Value = 6.82b USD (7.35b + Debt 10.5m - CCE 543.0m)
Interest Coverage Ratio = -10.58 (Ebit TTM -325.9m / Interest Expense TTM 30.8m)
FCF Yield = -4.66% (FCF TTM -317.9m / Enterprise Value 6.82b)
FCF Margin = -621.2% (FCF TTM -317.9m / Revenue TTM 51.2m)
Net Margin = -654.4% (Net Income TTM -334.9m / Revenue TTM 51.2m)
Gross Margin = -217.5% ((Revenue TTM 51.2m - Cost of Revenue TTM 162.5m) / Revenue TTM)
Gross Margin QoQ = 94.71% (prev -964.0%)
Tobins Q-Ratio = 8.83 (Enterprise Value 6.82b / Total Assets 772.0m)
Interest Expense / Debt = 292.8% (Interest Expense 30.8m / Debt 10.5m)
Taxrate = -6.48% (negative due to tax credits) (4.97m / -76.6m)
NOPAT = -347.0m (EBIT -325.9m * (1 - -6.48%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 7.97 (Total Current Assets 590.8m / Total Current Liabilities 74.1m)
Debt / Equity = 0.02 (Debt 10.5m / totalStockholderEquity, last quarter 661.6m)
Debt / EBITDA = 0.94 (negative EBITDA) (Net Debt -303.2m / EBITDA -323.7m)
Debt / FCF = 0.95 (negative FCF - burning cash) (Net Debt -303.2m / FCF TTM -317.9m)
Total Stockholder Equity = 686.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -43.38% (Net Income -334.9m / Total Assets 772.0m)
RoE = -48.76% (Net Income TTM -334.9m / Total Stockholder Equity 686.9m)
RoCE = -46.77% (EBIT -325.9m / Capital Employed (Equity 686.9m + L.T.Debt 9.91m))
RoIC = -49.91% (negative operating profit) (NOPAT -347.0m / Invested Capital 695.3m)
WACC = 9.18% (E(7.35b)/V(7.36b) * Re(9.19%) + (debt cost/tax rate unavailable))
Discount Rate = 9.19% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 14.40%
Fair Price DCF = unknown (Cash Flow -317.9m)
EPS Correlation: -26.60 | EPS CAGR: 5.66% | SUE: 2.29 | # QB: 1
Revenue Correlation: -5.97 | Revenue CAGR: -5.69% | SUE: 0.23 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-1.29 | Chg30d=+0.086 | Revisions Net=+2 | Analysts=6
EPS next Year (2026-12-31): EPS=-4.63 | Chg30d=-0.062 | Revisions Net=+0 | Growth EPS=+21.0% | Growth Revenue=-10.1%

Additional Sources for MRUS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle